NCT00828737View on ClinicalTrials.gov

Safety of Gadovist in Renally Impaired Patients

PHASE4CompletedINTERVENTIONAL

Enrollment

927

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

January 31, 2015

Study Completion Date

January 31, 2015

Conditions

FibrosisRenal Impairment

Interventions

DRUG

Gadobutrol (Gadovist, BAY86-4875)

Gadovist in approved indications at approved dosages

Trial Locations (70)

1030

Vienna

1090

Vienna

2145

Westmead NSW

3168

Clayton

3220

Geelong

4031

Basel

5000

Adelaide

6020

Innsbruck

6600

Ehenbichl

6900

Lugano

8036

Graz

8700

Leoben

10126

Torino

10700

Bangkok

12200

Berlin

12351

Berlin

13385

Marseille

16132

Genova

16816

Neuruppin

18012

Granada

20089

Rozzano

20132

Milan

20141

Milan

21031

Hamburg

25123

Brescia

31100

Treviso

34346

Hannoversch Münden

37134

Verona

39120

Magdeburg

44263

Dortmund

45122

Essen

49076

Osnabrück

50139

Florence

51092

Reims

56124

Pisa

58515

Lüdenscheid

59037

Lille

60126

Ancona

60596

Frankfurt am Main

68167

Mannheim

72076

Tübingen

75908

Paris

80131

Napoli

81377

München

90110

Songkhla

91054

Erlangen

93053

Regensburg

94275

Le Kremlin-Bicêtre

96450

Coburg

T2N 2T9

Calgary

L8N 4A6

Hamilton

M4N 3M5

Toronto

M5G 2N2

Toronto

J1H 5N4

Fleurimont

01307

Dresden

04289

Leipzig

07548

Gera

00161

Roma

00168

Roma

463-707

Seongnam-si

110-744

Seoul

602-739

Busan

561-712

Jeonju-Si, Jeonrabuk-Do

120-752

Seoul

135-710

Seoul

137-701

Seoul

138-736

Seoul

08036

Barcelona

08208

Sabadell

Unknown

Bangkok

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Bayer

INDUSTRY